Hypomagnesemia during teriparatide treatment in osteoporosis: Incidence and determinants
Journal of Bone and Mineral Research Jun 01, 2018
Bégin MJ, et al. - In this retrospective cohort study, researchers sought to ascertain the incidence of hypomagnesemia (serum magnesium <0.7 mmol/L) associated with teriparatide and identify the predisposing factors to hypomagnesemia. Between May 2008 and January 2016, the files of 53 patients treated for severe osteoporosis with teriparatide for 6 to 24 months were reviewed. In patients treated with teriparatide for severe osteoporosis, a statistically significant decrease in the serum magnesium levels was observed. Significant determinants of hypomagnesemia were older age and lower baseline magnesium. The findings suggested that closer monitoring of serum magnesium level should be considered in patients treated with teriparatide for severe osteoporosis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries